Join us for an exclusive and thought-provoking interview with Dr. Bob Hariri, Chairperson, Founder, and Chief Executive Officer of Celularity (NASDAQ: CELU), as he shares the company’s latest advancements and its bold vision for the future of cellular medicine. In this in-depth conversation, Dr. Hariri explains how Celularity is pioneering a new era of allogeneic, off-the-shelf cell therapies derived from the human placenta, and how the company’s innovations are poised to transform the way diseases are treated and patient outcomes are improved.
Dr. Hariri begins by laying out Celularity’s foundational philosophy: that the placenta, long seen merely as a byproduct of birth, holds exceptional potential as a scalable and ethically sourced platform for next-generation therapies. He discusses Celularity’s mission to harness this biological resource to create safe, potent, and readily available natural killer (NK) cell therapies designed to combat cancer, immune disorders, degenerative conditions, and even age-related diseases. According to Dr. Hariri, the company’s approach represents a dramatic shift in how medicine can be delivered—moving away from individualized, time-consuming cell harvesting toward universal cell products that can be stored, distributed, and administered when patients need them most.
The interview then turns to one of the company’s most anticipated scientific milestones: the presentation of new data at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. Dr. Hariri offers an early look at findings that highlight the potential of Celularity’s placental-derived natural killer cells to target and eliminate senescent cells—damaged and aging cells that accumulate in the body and contribute to chronic disease and tissue decline. This research, he explains, has implications not only for oncology but for regenerative medicine and longevity science, making it a focal point for investors, clinicians, and biotech observers.
Dr. Hariri also discusses the expanding clinical relevance of Biovance® 3L, one of Celularity’s most advanced biomaterial products. He explains how Biovance® 3L supports wound repair, tissue regeneration, and surgical healing, and why receiving a dedicated HCPCS Q code from the Centers for Medicare and Medicaid Services marks a significant step forward in reimbursement access and commercial scalability. With growing adoption across clinical settings, Biovance® 3L is positioned to become a cornerstone product in regenerative care.
The conversation continues with a deep dive into Celularity’s therapeutic candidate PDA-002, a placental-derived cell therapy currently advancing toward a Phase 1/2 study for Facioscapulohumeral Muscular Dystrophy (FSHD). Dr. Hariri explains why this therapy holds promise for addressing a rare, debilitating muscle disorder and how the company’s Orphan Drug Designation request could accelerate development and regulatory support. He also reflects on broader opportunities to expand PDA-002 into additional indications where inflammation, fibrosis, and muscle degeneration play a role.
Throughout the interview, Dr. Hariri shares insights drawn from his recent presentations at the ABUNDANCE Longevity Summit and the SBMT Annual World Congress. He discusses the emerging role of immunotherapy in promoting healthier aging and how placental-derived cellular platforms may open new frontiers for regenerative and longevity-focused medicine. These themes tie directly into Celularity’s long-term commitment to developing therapies that not only treat disease, but restore biological function and extend quality of life.
The discussion concludes with an overview of Celularity’s financial performance and growth prospects. Dr. Hariri highlights recent net sales achievements, ongoing operational improvements, and the strategic priorities designed to position Celularity for sustainable expansion. As the company advances key clinical programs, expands its commercial product portfolio, and deepens its scientific partnerships, Dr. Hariri remains confident that Celularity is building a powerful foundation for future success.
This conversation offers an invaluable look at the rapidly evolving landscape of cellular medicine and provides investors, clinicians, and biotechnology enthusiasts with a rare opportunity to hear directly from one of the field’s most influential voices.
CHECK THIS OUT: Why Nebius (NBIS) Could Outperform CoreWeave & Dominate the $9B AI Infrastructure Market and Is Lucid Group (LCID) Running Out of Cash? $875M Note Deal Raises Alarms.
About Celularity (NASDAQ: CELU)
Celularity Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic, off-the-shelf natural killer (NK) cell therapies and biomaterial products derived from the human placenta. Founded by renowned surgeon, scientist, and entrepreneur Dr. Bob Hariri, Celularity leverages the placenta’s unique immunological and regenerative properties to create scalable cellular therapies that can be manufactured at large volumes, shipped globally, and administered without the need for patient-specific cell sourcing.
The company’s pipeline and commercial product portfolio span oncology, regenerative medicine, immunology, and longevity applications. Its investigational therapies—including placenta-derived NK cells and PDA-002—aim to address unmet needs in cancer and rare diseases. Celularity’s commercial products, such as Biovance® and Biovance® 3L, are used in a growing number of clinical settings to support tissue repair and healing. With facilities in New Jersey and an expanding global footprint, Celularity is committed to revolutionizing patient care by delivering advanced cellular therapies that are accessible, durable, and scientifically transformative.
READ ALSO: Above Food (ABVE) to Issue 1.1 Billion New Shares in Merger and Perpetua Resources (PPTA) Soars 171% as U.S. Approves $1.3B Gold-Antimony Mine.
